In one paragraphArticle in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors at 2 institutions in 1 country.
Teodorus Theo SusantoDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-5537-3360 Victoria HungDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2716-4040 Andrew G LevineDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Craig H KerrDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-4793-2855 Yongjin YooInstitute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-4821-5233 Yuxiang ChenDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Juan A Oses-PrietoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0003-4759-2341 Kotaro FujiiDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6028-4776 Marius WernigInstitute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-5309-515X Alma L BurlingameDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-8403-7307 Davide RuggeroDepartment of Urology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9444-5865 Stanford University · USUniversity of California, San Francisco · US
Funding
Mechanisms of regulated translation control in cancer and its therapeutic implicationsR35CA242986 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUGGERO, DAVIDE · 2019 to 2025
$6.4MSpecialized Translational Control of Stem Cell Differentiation and Embryonic DevelopmentR01HD086634 · NICHD · STANFORD UNIVERSITY · PI BARNA, MARIA · 2016 to 2025
$5.5MRapid remodeling of the translatome underlying wound healing and regenerationR01HD105731 · NICHD · STANFORD UNIVERSITY · PI Maria Barna · 2022 to 2026
$1.7MEnhancing Resident Investigation and Career Advancement in Cardiovascular and Pulmonary ScienceR38HL143581 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIBBINS-DOMINGO, KIRSTEN, HUANG, ALISON · 2018 to 2021
$1.4MA ribosome interactome that regulates local translation and neural functionR21MH130323 · NIMH · STANFORD UNIVERSITY · PI BARNA, MARIA · 2022 to 2023
$433kControl of ribosomal function in cells of the hematopoietic systemK38HL165490 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEVINE, ANDREW · 2022 to 2023
$222kNCI NIH HHS R35 CA242986NHLBI NIH HHS K38 HL165490NHLBI NIH HHS R38 HL143581NICHD NIH HHS R01 HD086634NICHD NIH HHS R01 HD105731NIMH NIH HHS R21 MH130323
6 · The paper itselfAbstract
Ribosomes are emerging as direct regulators of gene expression, with ribosome-associated proteins (RAPs) allowing ribosomes to modulate translational control. However, a lack of technologies to enrich RAPs across many sample types has prevented systematic analysis of RAP number, dynamics, and functions. Here, we have developed a label-free methodology called RAPIDASH to enrich ribosomes and RAPs from any sample. We applied RAPIDASH to mouse embryonic tissues and identified hundreds of potential RAPs, including DHX30 and LLPH, two forebrain RAPs important for neurodevelopment. We identified a critical role of LLPH in neural development that is linked to the translation of genes with long coding sequences. Finally, we characterized ribosome composition remodeling during immune activation and observed extensive changes post-stimulation. RAPIDASH has therefore enabled the discovery of RAPs ranging from those with neuroregulatory functions to those activated by immune stimuli, thereby providing critical insights into how ribosomes are remodeled.
Indexed as
embryonic developmentmacrophagesproteomicsribosomeribosome-associated proteinsribosome heterogeneitytranslational control
Identifiers
PMID38106052
PMCPMC10723405
OpenAlexW4389426446
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390